Autophagy in hepatic ischemia-reperfusion injury
- PMID: 37019879
- PMCID: PMC10076300
- DOI: 10.1038/s41420-023-01387-0
Autophagy in hepatic ischemia-reperfusion injury
Erratum in
-
Correction: Autophagy in hepatic ischemia-reperfusion injury.Cell Death Discov. 2023 May 5;9(1):146. doi: 10.1038/s41420-023-01436-8. Cell Death Discov. 2023. PMID: 37147309 Free PMC article. No abstract available.
Abstract
Hepatic ischemia-reperfusion injury (HIRI) is a major complication of liver resection or liver transplantation that can seriously affect patient's prognosis. There is currently no definitive and effective treatment strategy for HIRI. Autophagy is an intracellular self-digestion pathway initiated to remove damaged organelles and proteins, which maintains cell survival, differentiation, and homeostasis. Recent studies have shown that autophagy is involved in the regulation of HIRI. Numerous drugs and treatments can change the outcome of HIRI by controlling the pathways of autophagy. This review mainly discusses the occurrence and development of autophagy, the selection of experimental models for HIRI, and the specific regulatory pathways of autophagy in HIRI. Autophagy has considerable potential in the treatment of HIRI.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Hippo (YAP)-autophagy axis protects against hepatic ischemia-reperfusion injury through JNK signaling.Chin Med J (Engl). 2024 Mar 20;137(6):657-668. doi: 10.1097/CM9.0000000000002727. Epub 2023 May 26. Chin Med J (Engl). 2024. PMID: 37232477 Free PMC article.
-
Pretreatment with the ALDH2 activator Alda‑1 protects rat livers from ischemia/reperfusion injury by inducing autophagy.Mol Med Rep. 2020 Sep;22(3):2373-2385. doi: 10.3892/mmr.2020.11312. Epub 2020 Jul 8. Mol Med Rep. 2020. PMID: 32705206 Free PMC article.
-
MCTR1 inhibits ferroptosis by promoting NRF2 expression to attenuate hepatic ischemia-reperfusion injury.Am J Physiol Gastrointest Liver Physiol. 2022 Sep 1;323(3):G283-G293. doi: 10.1152/ajpgi.00354.2021. Epub 2022 Aug 2. Am J Physiol Gastrointest Liver Physiol. 2022. PMID: 35916424
-
Research progress of lncRNA and miRNA in hepatic ischemia-reperfusion injury.Hepatobiliary Pancreat Dis Int. 2023 Feb;22(1):45-53. doi: 10.1016/j.hbpd.2022.07.008. Epub 2022 Jul 30. Hepatobiliary Pancreat Dis Int. 2023. PMID: 35934611 Review.
-
New progress in understanding roles of nitric oxide during hepatic ischemia-reperfusion injury.World J Hepatol. 2022 Mar 27;14(3):504-515. doi: 10.4254/wjh.v14.i3.504. World J Hepatol. 2022. PMID: 35582289 Free PMC article. Review.
Cited by
-
Unraveling the Multifaceted Roles of Extracellular Vesicles: Insights into Biology, Pharmacology, and Pharmaceutical Applications for Drug Delivery.Int J Mol Sci. 2023 Dec 29;25(1):485. doi: 10.3390/ijms25010485. Int J Mol Sci. 2023. PMID: 38203656 Free PMC article. Review.
-
XBP1 Facilitating NF-κB-p65 Nuclear Translocation Promotes Macrophage-Originated Sterile Inflammation Via Regulating MT2 Transcription in the Ischemia/Reperfusion Liver.Cell Mol Gastroenterol Hepatol. 2024;18(6):101402. doi: 10.1016/j.jcmgh.2024.101402. Epub 2024 Sep 12. Cell Mol Gastroenterol Hepatol. 2024. PMID: 39271015 Free PMC article.
-
Activation of AMPK/mTOR-Driven Autophagy and Suppression of the HMGB1/TLR4 Pathway with Pentoxifylline Attenuates Doxorubicin-Induced Hepatic Injury in Rats.Pharmaceuticals (Basel). 2024 May 26;17(6):681. doi: 10.3390/ph17060681. Pharmaceuticals (Basel). 2024. PMID: 38931349 Free PMC article.
-
Targeting NF-κB in Hepatic Ischemia-Reperfusion Alleviation: from Signaling Networks to Therapeutic Targeting.Mol Neurobiol. 2024 Jun;61(6):3409-3426. doi: 10.1007/s12035-023-03787-w. Epub 2023 Nov 22. Mol Neurobiol. 2024. PMID: 37991700 Review.
-
Protective effect of irbesartan against hepatic ischemia-reperfusion injury in rats: role of ERK, STAT3, and PPAR-γ inflammatory pathways in rats.Naunyn Schmiedebergs Arch Pharmacol. 2024 Aug 21. doi: 10.1007/s00210-024-03301-6. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 39167169
References
Publication types
Grants and funding
- 2020A1515010799/Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation)
- 2020A1515010799/Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation)
- 2020A1515010799/Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation)
- 2020A1515010799/Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation)
- 2020A1515010799/Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation)
- 81974442/National Natural Science Foundation of China (National Science Foundation of China)
- 81974442/National Natural Science Foundation of China (National Science Foundation of China)
- 81974442/National Natural Science Foundation of China (National Science Foundation of China)
- 81974442/National Natural Science Foundation of China (National Science Foundation of China)
- 81974442/National Natural Science Foundation of China (National Science Foundation of China)
LinkOut - more resources
Full Text Sources